

May 9, 2014

Announcements

Head & Neck Cancer Screening a Success

Thank you to the entire team of physicians and staff who worked together to ensure the success of the 2014 Free Head & Neck Cancer Screening Program at our St. Raphael and Yale-New Haven campuses. Together over 425 people were screened for head and neck malignancies, and 19 people were referred for follow-up evaluations with the Head & Neck Cancer Program at Smilow Cancer Hospital.

Frank Slack Departing Yale

Frank Slack, PhD, Professor of Molecular, Cellular, & Developmental Biology and Co-Leader of our Cancer Genetics and Genomics Research Program, will be leaving Yale on July 1, 2014 for a position at Harvard. This is bittersweet news because although Frank has been a tremendously valued colleague to so many of us at the Cancer Center, he has taken on an exciting opportunity in Boston and I am confident that he will continue to excel in this new role.

Frank plans to transition his lab and his Cancer Genetics and Genomics Research Program leadership responsibilities over the summer, and will continue to interact with many of his Yale collaborators during this time and beyond. We are planning a celebration of Frank's service to Yale Cancer Center in June and Hilary Prosnitz will be in touch with additional details. I hope you will join me in wishing Frank all the best as he begins this new chapter.

Yale Cancer Center Participation in ASCO

I am looking forward to seeing many of you at the ASCO Annual meeting in Chicago later this month. A full list of Yale Cancer Center's participation in the meeting will be featured in

from the desk of

Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer
Hospital at Yale-New Haven



Recent News

Read recent articles featuring experts from Yale Cancer Center [News Center >>](#)

LATEST ARTICLES:



Blementhal Blasts Blueberry Blast

APRIL 29, 2014

[Read More >>](#)



Pfizer Drops Less-Is-More Strategy With AstraZeneca Bid

APRIL 29, 2014

[Read More >>](#)

the May 23 issue of DirectConnect. If you are attending the meeting, and would like to join Yale Cancer Center's ASCO Twitter Team, please contact [Vicky Agnew](#). In the meantime, here is a list of lead author participation from Yale for your review:

Scott Gettinger

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

Poster Highlights Session

Mario Sznol

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558,

ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Oral Abstract Session

Joanne Weidhaas

The KRAS-variant and cetuximab response in RTOG 0522.

Oral Abstract Session

Diana English

Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after leep or conization.

General Poster Session

Nina Kadan-Lottick

Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children's Oncology Group (COG) AALL0932.

General Poster Session

Roxanne Wadia



Costly Breast Cancer Treatment More Common At For-Profit Hospitals
APRIL 28, 2014

[Read More >>](#)

Follow Yale Cancer Center on Twitter

Follow us on **twitter**

LATEST TWEETS:

@politikaterina: our latest paper on mTORC1 and resistance in EGFR mutant lung cancer @CellReports

@ysph @ysm experts @STMYale and @DrRoyHerbstYale are in DC today urging CT legislators to continue to support @NIH funding. #CancerResearch

New trial @YaleCancer for patients with Advanced Renal Cell Carcinoma (RCC) #kidneycancer: Study of MPDL3280A bit.ly/1ndZmtJ

Connecticut legislature unanimously passed a bill banning the sale of e-cigarettes to minors.

At this point I would not use

Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS).

General Poster Session

Daniel Boffa

Postoperative chemotherapy as effective as preoperative for N2-positive stage III non-small cell lung cancer.

General Poster Session

Erikka Loftfield

Effect of weight loss intervention on inflammatory and metabolic markers in breast cancer survivors: The lifestyle, exercise, and nutrition (LEAN) study.

Oral Abstract Session

Sarah Goldberg

Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma.

General Poster Session

Joanne Weidhaas

The KRAS-variant and treatment response in BATTLE-1.

General Poster Session

Howard Hochster


E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

General Poster Session

Jason Brown

Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.

PD-L1 assays to predict resp. in pts. Need phase III trials to further study anti-PD-1 therapy. Dr. Mario Sznol


 @YalePsych: Amoxicillin to Zolof: History of drug development chronicled ow.ly/wlyJp.

Join Yale Cancer Center on Facebook

[Like us on Facebook !\[\]\(1ed10657a19f9137278430c48fd18626_img.jpg\)](#)

LATEST POSTS:

#TBT The launch of the National Cancer Institute (NCI) Cancer Information Service at Yale Cancer Center in 1976. Yale Cancer Center operated telephone service for the Information Service up until 2005.



[Read More >>](#)

In recognition of National Nurses Week, Yale Cancer Center thanks all of the nearly 400 oncology nurses on staff at Smilow Cancer Hospital and in our 8 Cancer Care Centers throughout Connecticut for the amazing work they do each day to care for our patients. Their

Poster Highlights Session

Francine Foss

Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).

General Poster Session

Daniel Petrylak

A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.

General Poster Session

Joseph McLaughlin

Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).

General Poster Session

Roy Herbst

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.

General Poster Session

Scott Gettinger

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

General Poster Session

Kurt Schalper

Clinical significance of TILs subtypes in non-small cell lung cancer.

General Poster Session

Harriet Kluger

knowledge, compassion, and dedication is unsurpassed. Thank you for everything you do for our patients and their families!



[Read More >>](#)

Immunotherapies are quickly becoming a treatment option for more patients who are benefiting from recent research that harnesses the body's immune system to attack cancer. Dr. Mario Sznol at Yale Cancer Center led the way with a clinical trial for patients with advanced melanoma and renal cell carcinoma last year using anti-PD1 therapies in clinical trials. Now, researchers are looking for biomarkers and searching for ways to identify patients who will respond to these treatments.



[Read More >>](#)

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.

Poster Highlights Session

Daniel Yang

Estimating the impact of screening on three decades of cervical cancer incidence.

Poster Highlights Session

Francine Foss

Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.

General Poster Session

Daniel Petrylak

A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

Poster Highlights Session

Melinda Irwin

Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study.

Poster Highlights Session

James Yu

Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009.

General Poster Session

Edward James

Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel next-generation sequencing

Events

May 9; 7:30pm

Endocrine Tumor Board

NP4-215B

[Learn More >>](#)

May 9; 12:00pm

Research in Progress Lecture

Smilow Cancer Hospital,

4-101A

Investigation of Trametinib as a Potential Radio-sensitizer in Melanoma"

"Phase II Study of Modified Folfirinox in Advanced Pancreatic Cancer
Melinda Yushak, MD

Edward S. James, MD

[Learn More >>](#)

May 9; 1:00pm

Hematology/Leukemia Tumor Board

WWW 208

[Learn More >>](#)

May 9; 1:00pm

Molecular Virology Research Program

SHM I-116

In Vivo Imaging of Retroviral Spread
Xaver Sewald, PhD

[Learn More >>](#)

May 9; 1:15pm

Neuro-Oncology Tumor Board

NP4-215B

[Learn More >>](#)

May 11; 6:00pm

Yale Cancer Center Answers

method.

General Poster Session

Yale Cancer Center Participates in Hill Day

Roy Herbst, MD, PhD and Susan Mayne, PhD traveled to Washington, DC this week with Vicky Agnew, Senior Communications Officer for Yale Cancer Center, to participate in Hill Day with The American Association for Cancer Research, Association of American Cancer Institutes, American Society of Clinical Oncology, and Friends of Cancer Research to meet with Connecticut's delegation and to remind them of the impact investment in cancer research is making on our patients' lives and research progress here at Yale Cancer Center and Smilow Cancer Hospital.



Vicky Agnew, Rep. Chris Murphy Susan Mayne, Rep. Rosa DeLauro
Chris Zurawsky (AACI), Roy Herbst Roy Herbst

Medical Oncology and Hematology Teaching Prizes

Yale Cancer Center is accepting nominations from current fellows for the David S. Fischer Teaching Award for the best teacher/mentor from both the medical oncology faculty and the hematology faculty, including the medical staff at the West Haven Veterans Administration Hospital. Please consider effectiveness as a teacher and mentor, involvement in clinical conferences and lectures, and "bedside teaching" when choosing your nominations. The awards will be given out at the graduation dinner. Please contact [Savannah Woods](#) for a nomination form or for more information. Nominations are due to Savannah by June 1st.

Notables

WNPR 90.5

Ovarian Cancer Screening
Heather Glazer & Rachel Hayes
[Learn More >>](#)

May 12; 7:30am Thoracic Oncology Tumor Board

Smilow Cancer Hospital,
NP 4-215B
[Learn More >>](#)

May 12; 12:00pm Genitourinary (GU) Tumor Board

NP4-215B
[Learn More >>](#)

May 12; 3:00pm Head & Neck Tumor Board

NP4-215B

[Learn More >>](#)

May 12; 3:00pm Signal Transduction Research Program Conference

SHM I-116

*Stem Cell Contribution to
Squamous Tumors*
Valerie Horsley, MD
[Learn More >>](#)

May 12; 4:30pm Precision Medicine Tumor Board NP4-215B

[Learn More >>](#)

May 13; 8:30am Lymphoma/Stem Cell Meeting

NP4-215B
[Learn More >>](#)

May 13; 9:30am Pathology Research in Progress Talks

The Anlyan Center Auditorium,
N-107

TBA
Qi Li PhD; Xiaoling Song PhD
[Learn More >>](#)

May 13; 12:00pm Yale Cancer Center Grand Rounds/Dr. Joseph R. and

Cary Gross, MD has been awarded a 3-year grant from the **American Cancer Society** totaling \$592,000 to study cancer disparities. His study will provide a timely assessment of personalized cancer care patterns and their impact on cancer equity, and identify potential leverage points to ensure optimum access to this novel and increasingly important aspect of cancer care.

Second year Radiation Oncology Resident, **Brandon R. Mancini, MD** has been elected **Executive Committee Chair of the Association of Residents in Radiation Oncology (ARRO)** for 2014-2015. ARRO is a national organization representing residents in Radiation Oncology in the United States. In this role, he will lead the ARRO Executive Committee in multiple initiatives to improve education and create opportunities for residents, act as a liaison between ARRO and the American Society for Radiation Oncology (ASTRO) leadership, and serve on several ASTRO committees as a Resident Representative.

Alanna Schepartz, PhD, Milton Harris Professor of Chemistry and Professor of Molecular, Cellular & Developmental Biology, and a member of Yale Cancer Center's Developmental Therapeutics Program, has been elected into the **National Academy of Sciences**.

David Schatz, PhD, Professor of Immunobiology and of Biophysics and Biochemistry and a member of Yale Cancer Center's Immunology and Immunotherapy Program, has been elected into the **American Academy of Arts and Sciences**.

Roy Herbst, MD, PhD participated in the **National Forum on the Future of Health Care** at the National Press Club in Washington, DC last week and presented on *Research in the Age of Personalized Medicine: Lung Cancer Master Protocol*.

Daniel Petrylak, MD presented a poster during the 29th Annual EAU Congress in Stockholm, which was awarded a best poster award during the meeting. *A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC)*.

Narendra Wajapeyee, MD has published *Cancer Genomics and Proteomics: Methods and Protocols*, as part of the Methods in Molecular Biology Book Series.

Nancy Bove Transfusion Medicine Visiting Professorship Lecture
Park Street Auditorium

Cord Blood Banking and Transplantation: From Blood to Brain

Joanne Kurtzberg, PhD
[Learn More >>](#)

May 13; 12:00pm
Yale Cancer Center Grand Rounds/Bove Lecture
Smilow Auditorium

Cord Blood Banking and Transplantation: From Blood to Brain

Joanne Kurtzberg, MD
[Learn More >>](#)

May 13; 4:30pm
Gastrointestinal Tumor Board
Smilow, NP4-215B
[Learn More >>](#)

May 13 4:30pm
Gynecologic Oncology
Conference 621 EP 2nd Floor

[Learn More >>](#)

May 13; 5:00pm
Transforming Healthcare Grand Rounds
Fitkin Amphitheatre, LMP 1094

Synergies Between the Design and Execution of Quality Improvement Projects and Success at Writing Them Up for Publication

Kaveh G. Shojania, MD
[Learn More >>](#)

May 13; 5:30pm
Stem Cell Transplant Support Group
[Learn More >>](#)

May 14; 7:00am
The Yale Stress Center Class
Suite 209

Therapeutic Yoga
Anne Dutton, MA, RYT
[Learn More >>](#)

May 14; 11:00am
Radiobiology and Radiotherapy Research

Vincent DeVita Meets with Fellows

Hosted by Roy Herbst, MD, PhD, Vincent T. DeVita, Jr., MD attended a dinner with the medical oncology and hematology fellows earlier this month to share his perspective on progress in cancer care and treatment over the last 50 years, and in his own area of expertise, Hodgkin's Disease.



Closer to Free

Program

SHM I-304

Establishing a Role for Nuclear Envelope Bridging Proteins in Homology-Directed Repair
Rebecca Swartz

[Learn More >>](#)

May 14; 12:00pm

Thoracic Oncology Meeting
Smilow Cancer Hospital,

NP 4-215B

Lung Cancer Case Presentation
[Learn More >>](#)

May 14; 4:30pm

Breast Tumor Board

NP4-215B

[Learn More >>](#)

May 15; 7:30am

Melanoma Tumor Board

NP4-215B

[Learn More >>](#)

May 15; 9:00am

Therapeutic Radiology Grand Rounds

Smilow, LL-412, Room E

Journal Club

Joseph Contessa, MD, PhD

[Learn More >>](#)

May 15; 12:00pm

Schwartz Center Rounds

Smilow Auditorium

Thomas J. Lynch Jr., MD

[Learn More >>](#)

May 15; 12:30pm

Gastrointestinal Cancer Multidisciplinary Intake Conference

NP4-215B

[Learn More >>](#)

May 15; 1:30pm

Liver Tumor Board

NP4-215B

[Learn More >>](#)

May 15; 4:00pm

Pediatric Tumor Board

Celebrity Bartender Day at Augur's Irish Pub 29 Water Street, Guilford, CT SUNDAY, MAY 18th 1:00pm - 6:00pm

Please consider supporting this event
with merchandise or a gift certificate for the raffle!

Proceeds will benefit the Closer to Free Ride for Smilow Cancer Hospital



Funding and Award Opportunities

Hartwell Postdoctoral Fellowship

The Hartwell Foundation has provided a two-year fellowship for a postdoctoral trainee at Yale School of Medicine who is conducting research to benefit children.

Eligibility:

- Applicants must be postdoctoral fellows/associates with an M.D. or Ph.D. degree.
- They must be U.S. citizens.
- The proposed research must benefit children, particularly in the U.S., and the project should involve early-stage, innovative, high-risk biomedical research that has the potential to be transformative.
- The project should not yet have qualified for significant outside funding.

Key features of the fellowship include:

- \$50,000 per year for 2 years

NP4-215B

[Learn More >>](#)

**May 16; 7:30am
Endocrine Tumor Board**

NP4-215B

[Learn More >>](#)

**May 16; 10:30am
Sarcoma Tumor Board**

NP4-215B

[Learn More >>](#)

**May 16; 1:00pm
Hematology/Leukemia
Tumor Board**

WWW 208

[Learn More >>](#)

**May 16; 1:15pm
Neuro-Oncology Tumor
Board**

NP4-215B

[Learn More >>](#)

**May 18; 1:00pm
YCC / Closer To Free Benefit
Event**

Augur's Irish Pub

Celebrity Bartender Day

[Learn More >>](#)

**May 18; 6:00pm
Yale Cancer Center Answers
WNPR 90.5**

Brain Tumor Awareness

Jennifer Moliterno Gunel, MD

[Learn More >>](#)

**May 19; 7:30am
Thoracic Oncology Tumor
Board**

Smilow Cancer Hospital,
NP 4-215B

[Learn More >>](#)

**May 19; 12:00pm
Genitourinary (GU) Tumor
Board**

NP4-215B

[Learn More >>](#)

**May 19; 3:00pm
Head & Neck Tumor Board**

NP4-215B

[Learn More >>](#)

**May 19; 4:30pm
Precision Medicine Tumor**

- Start date between July 1 and November 1, 2014
- Funds may be used for salary, health insurance, and travel to scientific meetings, but not for supplies, equipment, other fringe benefits, or overhead.

Application Deadline: May 19, 2014

Contact: geraldine.emerling@yale.edu

Alex's Lemonade Stand Foundation

We are pleased to announce that grant guidelines and applications are now open for submission in the following categories:

'A' Awards

NEW in 2014, the award amount has increased to \$150,000 per year for three years! Designed for early career scientists with an original project who can demonstrate outstanding mentorship and have a strong future commitment to pediatric cancer investigation. This award totals \$450,000 over three years and is open to MD, MD/PhD and PhD candidates.

Application Deadline: May 23, 2014

Reach Awards

Our Reach Awards are designed to move hypothesis-driven research toward the clinic. The goal of this award is to support selected "late translational" studies needed to ultimately initiate a clinical trial. A successful application will identify an unmet clinical need relevant to the care of pediatric cancer patients and describe how the proposed project will allow for the pre-clinical research to be translated to the clinic while keeping broader clinical testing and implementation in view. Maximum of \$250,000 in total costs awarded over two years.

Application Deadline: May 30, 2014

[Learn More >>](#)

Lung Cancer Research Foundation Grants

Support research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. These awards are designed to provide critical seed support for cutting-edge scientific research on all lung cancers and will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes. Up to \$50,000 for 1 year.

Application Deadline: June 16, 2014

[Learn More >>](#)

Department of Defense Breast Cancer Research Program

Era of Hope Scholar Award

Independent, non-mentored investigators within 6 years

Board

NP4-215B

[Learn More >>](#)

May 19; 5:30pm Yale Cancer Center Thoracic Oncology Program

NP4-101B

Lung Cancer Support Group

Linda David, RN & Irene

Scanlon, LCSW

[Learn More >>](#)

May 20; 8:30am Lymphoma/Stem Cell Meeting

NP4-215B

[Learn More >>](#)

May 20; 9:30am Pathology Research in Progress Talks

The Brady Auditorium, BML 1st

Floor

TBA

Yalai Bai MD, PhD; Jie Li MD,

PhD

[Learn More >>](#)

May 20; 12:00pm Yale Cancer Center Grand Rounds

Smilow Auditorium

[Learn More >>](#)

May 20; 4:30pm Gastrointestinal Tumor Board

Smilow, NP4-215B

[Learn More >>](#)

May 20; 4:30pm Gynecologic Oncology Conference

621 EP 2nd Floor

[Learn More >>](#)

May 21; 7:00am The Yale Stress Center Class

Suite 209

Therapeutic Yoga

Anne Dutton, MA, RYT

[Learn More >>](#)

May 21; 12:00pm

of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

- Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the "best and brightest" in their fields.
- PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
- PIs should exhibit strong potential for leadership in the breast cancer community
- PIs must include breast cancer advocates on their research team.
- Maximum funding of \$2.5M for direct costs (plus indirect costs)
- Period of performance not to exceed 5 years

Letter of Intent Deadline: August 1, 2014

Application Deadline: August 15, 2014

Innovator Award

Associate Professor or above (or equivalent)

- Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.
- Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.
- PIs must include breast cancer advocates on their research team.
- Nomination is required; self-nominations are accepted; application submission is by invitation only.
- Maximum funding of \$5M for direct costs (plus indirect costs)
- Period of performance not to exceed 5 years

Nomination Deadline: May 14, 2014

Invited Application Deadline: August 15, 2014

Breakthrough Award

- Investigators at all academic levels (or equivalent)
- Postdoctoral fellows are eligible to apply
- Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
- Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
- Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
- Four different funding levels, based on the scope of research, are available. It is the responsibility of the PI to select the funding level that is most appropriate for

Thoracic Oncology Meeting

Smilow Cancer Hospital,

NP 4-215B

Lung Cancer Case Presentation

[Learn More >>](#)

May 21; 12:30pm

Yale Macrophage Café

SHM C-103

Home Seet Home: Legionella

Grows in the Macrophage

Stéphanie Shames, PhD

[Learn More >>](#)

May 21; 4:30pm

Breast Tumor Board

NP4-215B

[Learn More >>](#)

May 22; 7:30am

Melanoma Tumor Board

NP4-215B

[Learn More >>](#)

May 22; 9:00am

Therapeutic Radiology Grand Rounds

Smilow, LL-412, Room E

Exploring the Cost-

Effectiveness of Prostate Cancer Treatment

James Yu, MD

[Learn More >>](#)

May 22; 12:30pm

Gastrointestinal Cancer

Multidisciplinary Intake

Conference

NP4-215B

[Learn More >>](#)

May 22; 1:30pm

Liver Tumor Board

NP4-215B

[Learn More >>](#)

May 22; 4:00pm

Pediatric Tumor Board

NP4-215B

[Learn More >>](#)

May 23; 7:30am

Endocrine Tumor Board

the research proposed.

- Period of performance not to exceed 5 years

Letter of Intent Deadline: May 14, 2014

Full Application Deadline: May 28, 2014

[Learn More >>](#)

Recent Publications

Raising the Bar for the Care of Seriously Ill Patients: Results of a National Survey to Define Essential Palliative Care Competencies for Medical Students and Residents

Schaefer, Kristen G. MD; Chittenden, Eva H. MD; Sullivan, Amy M. EdD; Periyakoil, Vyjeyanth S. MD; Morrison, Laura J. MD; Carey, Elise C. MD; Sanchez-Reilly, Sandra MD; Block, Susan D. MD

[Read More >>](#)

SRF is required for neutrophil migration in response to inflammation

Taylor A, Tang W, Bruscia EM, Zhang PX, Lin A, Gaines P, Wu D, Halene S.

Blood. 2014 Feb 26.

[Read More >>](#)

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

Valentina Pirazzoli, Caroline Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M. Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David Carbone, Philip J Stephens, Vincent Miller, Scott Gettinger, William Pao and Katerina Politi
j.celrep.2014.04.014

[Read More >>](#)

Histone Demethylase Jumonji AT-Rich Interactive Domain 1B (JARID1B) Controls Mammary Gland Development by Regulating Key Developmental and Lineage Specification Genes.

Zou MR, Cao J, Liu Z, Huh SJ, Polyak K, Yan Q.

J Biol Chem. 2014 May 6.

[Read More >>](#)

Mapping the homodimer interface of an optimized, artificial, transmembrane protein activator of the human erythropoietin receptor.

Cohen EB, Jun SJ, Bears Z, Barrera FN, Alonso M, Engelman DM, Dimaio D.

PLoS One. 2014 Apr 30;9(4):e95593.

NP4-215B

[Learn More >>](#)

May 23; 1:00pm Hematology/Leukemia Tumor Board

WWW 208

[Learn More >>](#)

May 23; 1:15pm Neuro-Oncology Tumor Board

NP4-215B

[Learn More >>](#)

Employment Opportunities

Success in any clinical research endeavor, but especially in cancer research, requires the most qualified, dedicated staff, committed to excellence and the mission of Yale Cancer Center. The combination of education, oncology research experience, and exceptional nursing skills is enormously difficult to find. Your participation, as knowledgeable colleagues, is invaluable at this time.

Should you know individuals with outstanding clinical research nursing experience, and who are ready to join our team, please direct resumes to [Sandra Greer](#), Sr. Staffing and Career Development Representative or call (203) 432-5822. All referrals will be held in strictest confidence.

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 Forward to a Friend

[Read More >>](#)

For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.

Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP.
Surgery. 2014 May;155(5):776-88.

[Read More >>](#)

Hospital-based, acute care after ambulatory surgery center discharge.

Fox JP, Vashi AA, Ross JS, Gross CP.
Surgery. 2014 May;155(5):743-53.

[Read More >>](#)

Practical guide to the use of chemotherapy in castration resistant prostate cancer.

Petrylak DP.
Can J Urol. 2014 Apr;21(2 Supp 1):77-83.

[Read More >>](#)

Screening for prostate cancer: are digital rectal examinations being performed?

Federman DG, Pitkin P, Carbone V, Concato J, Kravetz JD.
Hosp Pract (1995). 2014 Apr;42(2):103-7.

[Read More>>](#)

O-GlcNAc signaling in cancer metabolism and epigenetics.

Singh JP, Zhang K, Wu J, Yang X.
Cancer Lett. 2014 Apr 24.

[Read More >>](#)

How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules.

Fonseca A, Detterbeck FC.
Lung Cancer. 2014 Mar 3.

[Read More >>](#)

Predictors of Pretreatment Commitment to Abstinence: Results from the COMBINE Study.

Demartini KS, Devine EG, Diclemente CC, Martin DJ, Ray LA, O'Malley SS.
J Stud Alcohol Drugs. 2014 May;75(3):438-46.

[Read More >>](#)

New developments in the treatment of castration resistant prostate cancer.

Wadia R, Petrylak DP.
Asian J Androl. 2014 Apr 8.

[Read More >>](#)

Experience with thoracoscopic pneumonectomies at a single institution.

Kim AW, Fonseca AL, Boffa DJ, Detterbeck FC.
Innovations (Phila). 2014 Mar-Apr;9(2):82-6.

[Read More >>](#)